Key facts
- This page summarizes Kevin E. Lofton's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 May 2022, 18:52.
Kevin E. Lofton - 05 May 2022 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)
- Reporting relationship
- Director
- Issuer ticker
- GILD
- Reported as of
- 05 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 May 2022, 18:52:42 UTC
- Prior SEC filing
- 03 May 2022
- Next SEC filing
- 30 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy Kim by Power of Attorney for Kevin E. Lofton
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kevin E. Lofton filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 06 May 2022.
Change
- Previous filing in this sequence was filed on 03 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GILD
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,444
- Change %
- +2.6%
- Price
- $0.000000
- Shares after
- 95,192
- Date
- 05 May 2022
- Ownership
- By Trust
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GILD
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,851
- Change %
- Price
- $0.000000
- Shares after
- 15,851
- Date
- 05 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,851
- Exercise price
- $61.35
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents 2.444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022.
Footnote F2
Includes 65,874 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust.
Footnote F3
100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.